By Chris Wack
Lipella Pharmaceuticals shares were up 37% to $4.18 after the company said it saw positive topline results from its Phase 2a dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus.
The biotechnology company said LP-310 demonstrated a strong safety profile, with no product-related serious adverse events and no patient dropouts.
Oral lichen planus is a chronic inflammatory condition that affects the mucous membranes inside the mouth, on the tongue, cheeks, gums or palate.
The trial showed statistically significant improvements across multiple patient-reported and investigator-measured efficacy endpoints at weeks one, four and six, Lipella said.
The trial, which is active across seven U.S. sites, has progressed to the next higher dose cohort of 0.5 mg/10 mL.
Lipella continues to recruit for the trial, with plans to activate additional sites and complete the trial by mid-2025. The company is preparing for key milestones, including the submission of a Phase 2b clinical trial investigational new drug application in the second half of 2025 and a breakthrough therapy designation request to the Food and Drug Administration during the same period.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 11, 2025 12:56 ET (17:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。